Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
- Kazuhiko Ezawa to Become Chuikyo JMA Rep after Matsumoto
October 28, 2021
- JGA Sets Out 5-Pronged Measures to Restore Trust in Generics
October 27, 2021
- Kenporen’s Masato Matsumoto to Take Over from Kono as Chuikyo Payer Rep
October 27, 2021
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- Choseido Suspended from JGA for 5 Years after Biz Suspension Order
October 15, 2021
- EFPIA to Ponder Position on Macroeconomic Indexing with Patient Access as Top Priority, Continue Dialogue with Japan Govt
October 14, 2021
- Plaintiffs, Lawyers Renew Opposition to Restart of HPV Vaccine Recommendation
October 13, 2021
- JGA Vows Strict Response to Choseido’s Biz Suspension Order
October 12, 2021
- IFPW Chair Vows to Boost Reliability of Healthcare Supply Chain as Tokyo Confab Ends
October 8, 2021
- INES’ Patient-Centered Policy Initiative Going Full Throttle, Proposal Eyed before 2022 Honebuto Paper
October 7, 2021
- JMA Exec Chides Pharma for Requesting Price Measure to Ensure Stable Supplies, Says Compliance System Should Come First
October 7, 2021
- Biocommunity for Greater Tokyo Area Boots Up, Aims to Form Bioinnovation Hub
October 7, 2021
- Amy Jackson to Leave PhRMA Japan, Kawabata to Take Up Interim Role
October 6, 2021
- 1,749 Generic Products Now under Supply Restrictions: JGA
October 5, 2021
- Think Twice before Issuing Long-Term Prescriptions for Supply-Curbed Generics: JMA
October 5, 2021
- MEJ Study Group Calls for Electronic Medical Chart Reform to Expedite Clinical Trials, New Drug Development
October 4, 2021
- FPMAJ to Define Shipment Situation in Preparation for Supply Information Centralization
October 1, 2021
- FPMAJ Chief Praises Political Acumen of New LDP Leader Kishida, Seeks Support for Industry
September 30, 2021
- Generic Use Rate Slips to 79.8% in April-June: JGA
September 30, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…